SA’s biggest pharmaceutical manufacturer, Aspen Pharmacare, is optimistic it can achieve double-digit operating profit growth over the next three years, and is considering adding additional assets to leverage the benefits of a torturous acquisition and build programme.

Aspen was among a host of companies that scrapped dividends in 2020 as it sought to preserve cash amid the uncertainty created by Covid-19, while hefty debt levels weighed on its market value and forced it to sell off assets recently...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now